From: Quantitative multiparametric MRI predicts response to neoadjuvant therapy in the community setting
Patient # | Age [years] | ER/PR/HER2 | Therapeutic regimen | Pathological response |
---|---|---|---|---|
1 | 54 | +/−/− | doxorubicin/cyclophosphamide → paclitaxel | Non-pCR |
2 | 41 | +/+/+ | doxorubicin/cyclophosphamide → paclitaxel/Herceptin | pCR |
3 | 74 | −/−/− | doxorubicin/cyclophosphamide → paclitaxel | Non-pCR |
4 | 25 | −/−/− | doxorubicin/cyclophosphamide → paclitaxel | Non-pCR |
5 | 26 | −/−/+ | doxorubicin/cyclophosphamide → paclitaxel /Herceptin | pCR |
6 | 41 | −/−/− | Carboplatin/paclitaxel → doxorubicin/cyclophosphamide | pCR |
7 | 37 | −/−/− | Carboplatin/paclitaxel → doxorubicin/cyclophosphamide | Non-pCR |
8 | 41 | +/−/− | doxorubicin/cyclophosphamide → paclitaxel | pCR |
9 | 47 | +/+/− | doxorubicin/cyclophosphamide → paclitaxel | pCR |
10 | 54 | +/+/− | doxorubicin/cyclophosphamide → paclitaxel | Non-pCR |
11 | 59 | −/−/− | Pembrolizumab (or placebo)/Carboplatin/paclitaxel | Non-pCR |
12 | 63 | +/+/− | doxorubicin/cyclophosphamide → paclitaxel | Non-pCR |
13 | 27 | +/+/− | doxorubicin/cyclophosphamide → paclitaxel | Non-pCR |
14 | 32 | +/+/+ | Taxotere/Carboplatin/Herceptin/Pertuzumab | Non-pCR |
15 | 52 | −/−/− | Carboplatin/paclitaxel → doxorubicin/cyclophosphamide | Non-pCR |
16 | 38 | −/−/− | Carboplatin/paclitaxel → doxorubicin/cyclophosphamide | pCR |
17 | 38 | −/−/− | Pembrolizumab (or placebo)/Carboplatin/paclitaxel | pCR |
18 | 62 | −/−/− | doxorubicin/cyclophosphamide → paclitaxel | Non-pCR |
19 | 38 | +/+/+ | Taxotere/Carboplatin/Herceptin/Pertuzumab | Non-pCR |
20 | 42 | +/+/− | doxorubicin/cyclophosphamide → paclitaxel | Non-pCR |
21 | 53 | +/+/− | doxorubicin/cyclophosphamide → paclitaxel | Non-pCR |
22 | 58 | −/−/− | Pembrolizumab (or placebo)/Carboplatin/paclitaxel | Non-pCR |
23 | 48 | +/+/− | doxorubicin/cyclophosphamide → paclitaxel | Non-pCR |
24 | 50 | +/+/+ | Taxotere/Carboplatin/Herceptin/Pertuzumab | Non-pCR |
25 | 64 | +/+/− | doxorubicin/cyclophosphamide → paclitaxel | Non-pCR |
26 | 40 | +/−/+ | Taxotere/Carboplatin/Herceptin/Pertuzumab | pCR |
27 | 31 | −/−/− | doxorubicin/cyclophosphamide → paclitaxel | Non-pCR |
28 | 54 | −/−/− | Talazoparib | Non-pCR |